Biologic Improves Nail Symptoms of Patients With PsA
Adalimumab (Humira) reduced nail and skin symptoms of patients with psoriatic arthritis (PsA), according to the findings of a recent study.
In their retrospective study, the researchers used data from the Royal National Hospital for Rheumatic Diseases cohort study to identify patients with PsA with nail involvement who were prescribed adalimumab. A total of 36 patients were included in the study, with a mean disease duration at baseline of 10.1 years. Data collected included demographics, Bath nail scores, and Psoriasis Area and Severity Index (PASI) scores, which were documented at 3, 6, 12, 18, 24, and 36 months.
PsA Action Month Helps Patients Live Their Best Lives
Efficacy of Biologic for PsA Confirmed in Phase 3 Trial
Is Long-term PsA Therapy Safe, Effective?
The mean nail score at baseline was 5.8 and mean PASI score was 5.0. After 6 months, the researchers observed significant reductions in the mean and median nail and PASI scores, which were maintained at 36 months.
Additionally, 62% of patients were found to have no disease activity based on nail scores and 35% of patients were found to have no activity based on PASI scores at 6 months. At 36 months 64% and 36% of patients had no disease activity based on nail and PASI scores, respectively.
“In this patient cohort, treatment with adalimumab led to overall reductions in nail and skin disease activity,” the researchers concluded.
McHugh N, Cavill C, Tillett W, Korendowych E, Hickey J, Mohammed D. Improvement of psoriatic nail disease in psoriatic arthritis patients treated with adalimumab: results of an observational cohort up to 36 months [published online April 25, 2018]. Rheumatology. https://doi.org/10.1093/rheumatology/key075.411